P0191: The role of myeloid mineralocorticoid receptor and its target neutrophil gelatinase-associated lipocalin in mice with colitis.ECCO'25Year: 2025
Authors: Rebollo, E.(1)*;Leboutte, M.(1);Jaisser , F.(2);Savoye, G.(3);Marion-Letellier, R.(1);
(1)Univ Rouen Normandie- INSERM- ADEN UMR1073- “Nutrition- Inflammation and microbiota-gut-brain axis”- F-76000 Rouen, UFR Santé Université de Rouen Normandie, Rouen, France;(2)Centre de Recherche des Cordeliers- Sorbonne Université- Inserm- Université Paris Cité- Team Diabetes- metabolic diseases and comorbidities- F-75006- Paris., Inserm- Université Paris Cité- Team Diabetes- metabolic diseases and comorbidities- F-75006- Paris., Paris, France;(3)Univ Rouen Normandie- INSERM- Normandie Univ- ADEN UMR1073- Nutrition- Inflammation and microbiota-gut-brain axis- CHU Rouen- Department of Gastroenterology- F-76000 Rouen- France, CHU Rouen- Department of Gastroenterology, Rouen, France;
P0192: Activities of Sorghum bicolor diet on microbial gut-brain axis during experimental Crohn’s Colitis in adult male Wistar rats.ECCO'25Year: 2025
Authors: SalamiPhD, A.T.(1)*;Akpamu, U.(2);Anyakudo, G.C.(3);Oluwakorede, T.S.(3);Olujimi , A.O.(3);Olaleye, B.S.(3);
(1)University of Ibadan, Department of Physiology, Ibadan, Nigeria;(2)Federal University Oye-Ekiti, Physiology, Oye-Ekiti, Nigeria;(3)University of Ibadan, Physiology, Ibadan, Nigeria;
P0193: Oral administration of Sophora Flavescens-derived exosomes-like nanovesicles carrying CX5461 ameliorates DSS-induced colitis in miceECCO'25Year: 2025
Authors: Dai, D.(1);Fang, C.(2)*;Hongbo, C.(2);Xichao, X.(1);
(1)Shenzhen Children’s Hospital, Endoscopy Center and Gastroenterology Department, Shenzhen, China;(2)Sun Yat-sen University, School of Pharmaceutical Sciences Shenzhen, Shenzhen, China;
[1] T. Kobayashi, B. Siegmund, C. Le Berre, S.C. Wei, M. Ferrante, B. Shen, C.N. Bernstein, S. Danese, L. Peyrin-Biroulet, T. Hibi, Ulcerative colitis, Nat Rev Dis Primers, 6 (2020) 74.
[2] X. Yan, L. Meng, X. Zhang, Z. Deng, B. Gao, Y. Zhang, M. Yang, Y. Ma, Y. Zhang, K. Tu, M. Zhang, Q. Xu, Reactive Oxygen Species-Responsive Nanocarrier Ameliorates Murine Colitis by Intervening Colonic Innate and Adaptive Immune Responses, Mol Ther, (2023).
[3] Y.N. Wang, J. Li, W.Y. Zheng, D. Wu, H. Yang, Y. Li, H. Lv, B. Tan, H.J. Shu, X.Y. Sun, J.M. Qian, B. Wu, J.N. Li, Clinical characteristics of ulcerative colitis-related colorectal cancer in Chinese patients, J Dig Dis, 18 (2017) 684-690.
[4] R. Ungaro, S. Mehandru, P.B. Allen, L. Peyrin-Biroulet, J.F. Colombel, Ulcerative colitis, Lancet, 389 (2017) 1756-1770.
P0195: Immune reconstitution following autologous hematopoietic stem cell transplantation with cyclophosphamide-free mobilization for refractory Crohn’s diseaseECCO'25Year: 2025
Authors: Saager, E.(1)*;Lutter, L.(2);Mahmmod, N.(3);Hoytema van Konijnenburg, D.(4);Delemarre, E.(1);van der Wal, M.(1);Oldenburg, B.(5);van Wijk, F.(1);Fidder, H.(5);
(1)University Medical Centre Utrecht, Centre for Translational Immunology, Utrecht, The Netherlands;(2)Amsterdam University Medical Centre, Pathology, Amsterdam, The Netherlands;(3)St. Antonius Ziekenhuis, Maag-- Darm- en Leverziekten, Utrecht, The Netherlands;(4)Boston Children's Hospital, Division of Immunology, Boston, United States;(5)University Medical Centre Utrecht, Maag-- Darm- en Leverziekten, Utrecht, The Netherlands;
P0196: Metabolic dysregulation in Crohn’s disease fibrosis: Targeting WISP1 to restore ECM homeostasisECCO'25Year: 2025
Authors: Buck, A.(1,2)*;Widemann, K.(1);Weber, M.C.(1);Friess, H.(1);Neumann, P.A.(1,2);
(1)Klinikum rechts der Isar- TU Munich, Department of Surgery, Munich, Germany;(2)Institute for Advanced Study, TU Munich, Munich, Germany;
P0197: Comparison of pharmacodynamic and mechanistic response of guselkumab intravenous and subcutaneous induction in moderately to severely active Crohn’s disease: molecular analysis of the GRAVITI and GALAXI Phase 3 studiesECCO'25Year: 2025
Authors: Richards, D.(1)*;Patel, R.(1);Sohn, K.(1);Hart, A.(1);Lee, T.(1);Liu, J.(1);Sisk, C.(1);Olurinde, M.(1);Terry, N.(1);McRae, B.(1);Reinisch, W.(2);Feagan, B.(3);Steinwurz, F.(4);Panaccione, R.(5);D’Haens, G.(6);Branigan, P.(1);
(1)Janssen Research & Development LLC, Research & Development, Spring House, United States;(2)Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria;(3)Alimentiv- Inc, Western University, London- Ontario, Canada;(4)Hospital Israelita Albert Einstein, Medical, São Paulo, Brazil;(5)Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Canada;(6)Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands;
1. Panaccione R, Danese S, Feagan BE, et al. Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn’s disease: results of the GALAXI 2 & 3 phase 3 studies. Gastroenterology. 2024; 5 (Supplement): p1057b.
2. Panaccione R, Hart A, Steinwurz F et al. Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients with Moderately to Severely Active Crohn's Disease: Results Through Week 48 From the Phase 3 GRAVITI Study. ACG 2024.
3. C Argmann, et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2022; 0:1-17.
4. Richards D, Venkat S, Ruane D, et al. Guselkumab Decreases Key Cellular Inflammatory Processes Across Ileum and Colon Tissue in Crohn’s Disease. P0950 ACG 2024.
P0198: Comparative Transcriptomic Analysis of Tonsil-derived and Adipose-derived Mesenchymal Stem Cells: Proliferation, Migration, and Anti-inflammatory Potential in Murine Colitis ModelECCO'25Year: 2025
Authors: Song, E.M.(1)*;Joo, Y.H.(1);Byeon, J.(1);Choe, A.R.(1);Park, Y.(1);Tae, C.H.(1);Kim, S.E.(1);Jung, H.K.(1);Shim, K.N.(1);Jung, S.A.(1);
(1)College of Medicine- Ewha Medical Research Institute- Ewha Womans University, Department of Internal Medicine, Seoul, Korea- Republic Of;
P0199: Development of a high-throughput multiplex immunofluorescence and an AI-assisted image analysis tool to study T cells dynamics in pre-clinical rodent models of IBDECCO'25Year: 2025
Authors: Preti, M.(1)*;Hofving, T.(1);Bretin, A.(1);Benonisson, H.(1);Gonzalez-King Garibotti, H.(1);Burgueno, J.(1);Borde, A.(1);Birrel, M.(2);Preite, S.(1);Piras, A.(1);
(1)AstraZeneca, Early Respiratory and Immunology Bioscience In Vivo, Mölndal, Sweden;(2)AstraZeneca, Early Respiratory and Immunology Bioscience In Vivo, London, United Kingdom;
P0200: Evaluating the efficacy of tonsil-derived mesenchymal stem cells and intestinal stem cells-like cells in modulating fibrosis and inflammation in murine colitis modelsECCO'25Year: 2025
Authors: Byeon, J.R.(1)*;Song, E.M.(1);Joo, Y.H.(1);Choe, A.R.(1);Park, Y.(1);Tae, C.H.(1);Kim, S.E.(1);Jung, H.K.(1);Shim, K.N.(1);Park, Y.S.(2);Jung, S.A.(1);
(1)Ewha Womans University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of;(2)Eulji university College of Medicine, Department of Internal Medicine-, Seoul, Korea- Republic Of;
P0201: Gut Bacteria Prevotellaceae Related Lithocholic Acid Metabolism Promotes Colonic InflammationECCO'25Year: 2025
Authors: Chen, L.(1)*;Ye, Z.(2);Li, J.(3);Xiao, F.(2);
(1)Tongji Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China;(2)Tongji Hospital- Tongji Medical College- Huazhong University of Science and Technology- Wuhan- China, Department of Gastroenterology, Wuhan, China;(3)Tongji Hospital- Tongji Medical College- Huazhong University of Science and Technology- Wuhan- China, Department of Nephrology, Wuhan, China;
1. Vich Vila A, Hu S, Andreu-Sanchez S, Collij V, Jansen BH, Augustijn HE, Bolte LA, Ruigrok R, Abu-Ali G, Giallourakis C, et al: Faecal metabolome and its determinants in inflammatory bowel disease. Gut 2023:1472-1485.
2. Hu H, Shao W, Liu Q, Liu N, Wang Q, Xu J, Zhang X, Weng Z, Lu Q, Jiao L, et al: Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion. Nat Commun 2022, 13:252.
3. He Z, Ma Y, Yang S, Zhang S, Liu S, Xiao J, Wang Y, Wang W, Yang H, Li S, Cao Z: Gut microbiota-derived ursodeoxycholic acid from neonatal dairy calves improves intestinal homeostasis and colitis to attenuate extended-spectrum beta-lactamase-producing enteroaggregative Escherichia coli infection. Microbiome 2022, 10:79.
4. Han B, Lv X, Liu G, Li S, Fan J, Chen L, Huang Z, Lin G, Xu X, Huang Z, et al: Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-alpha4beta7-integrin therapy in humanized mice with colitis. Gut Microbes 2023, 15:2232143.
P0203: Unique faecal & oral microbiota signatures in first degree relatives of inflammatory bowel disease patientsECCO'25Year: 2025
Authors: Koentgen, S.(1)*;Zhang, F.(1);Wu, N.(1);Jayawardana, T.(1);Little, R.(2);Tavakoli, P.(1);Ghaly, S.(3);Connor, S.J.(4);Hold, G.L.(1);
(1)University of New South Wales, Microbiome Research Centre, Sydney, Australia;(2)Alfred Hospital, Gastroenterology, Melbourne, Australia;(3)St Vincent’s Private Hospital Sydney, Gastroenterology, Sydney, Australia;(4)Liverpool Hospital, Gastroenterology and Liver, Sydney, Australia;
P0204: Impact of crypt niche factors and oxygen gradient on intestinal epithelial differentiation and inflammatory responseECCO'25Year: 2025
Authors: Dotti, I.(1,2)*;Rodríguez-Camejo , C.(3);Esteller, M.(1,2);Robbins, L.M.(1,2);Ricart, E.(1,2);Salas, A.(1,2);
(1)Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer FRCB-IDIBAPS, Inflammatory Bowel Disease Unit- Hospital Clínic de Barcelona, Barcelona, Spain;(2)Centro de Investigación Biomédica en Red, Enfermedades hepáticas y digestivas CIBEREHD, Barcelona, Spain;(3)Universidad de la República, Área Inmunología- Facultad de Química / Facultad de Ciencias- Instituto de Higiene, Montevideo, Uruguay;
1. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med. 2007;85(12):1295-1300.
2. Wang Y, Chiang IL, Ohara TE, et al. Long-Term Culture Captures Injury-Repair Cycles of Colonic Stem Cells. Cell. 2019;179(5):1144-1159.e15.
P0205: Fecal host transcriptomics accurately assesses endoscopic inflammatory activity in patients with inflammatory bowel diseasesECCO'25Year: 2025
Authors: Weintraub, Y.(1);Segal, A.(2);Matar, M.(1);Nevo-Shor, A.(2);Kantor, I.(2);Shamir, R.(1);Bahar Halpern, K.(3);Itzkovitz, S.(3);Yehuda-Cohen, A.(4);Kahan-Hanum, M.(4);Harnik, Y.(4);Shouval, D.(1)*;
(1)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petah Tikva, Israel;(2)Soroka University Medical Center, Department of Gastroenterology, Be'er Sheva, Israel;(3)Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot, Israel;(4)Tracells, Ltd., Kazrin, Israel;
P0206: Skin deep connections: patients with stricturing Crohn’s disease are more likely to have a history of skin scarring than those with non-stricturing Crohn’s and non-IBD controlsECCO'25Year: 2025
Authors: Mohamedrashed, M.(1);Yogakanthi, S.(1);Chauhan, A.(1);Lucas, S.(1);Robinson, A.(2);Garg, M.(1)*;
(1)Northern Health, Gastroenterology, Melbourne, Australia;(2)Northern Health, Dermatology, Melbourne, Australia;
P0207: Ex-vivo colonoids derived from ulcerative colitis patients retain epithelial inflammatory "memory" even after several passages, which may contribute to UC chronicityECCO'25Year: 2025
Authors: Abbas-Egbariya, H.(1);Braun, T.(1);Granot, M.(1);Weiss, B.(1);Gal-Mor, O.(2);Amir, A.(1);VanDussen, K.(1);Haberman Ziv, Y.(1)*;
(1)Sheba Medical Center, Gastro, Ramat Gan, Israel;(2)Sheba Medical Center, Microbiology, Ramat Gan, Israel;
P0208: Can we predict inflammatory activity of Ulcerative Colitis by just looking into eyes?ECCO'25Year: 2025
Authors: Tagluk, B.(1)*;Kav, T.(2);Keskin, O.(2);Kadayifcilar, S.(3);
(1)Hacettepe University, Internal Medicine, Ankara, Turkey;(2)Hacettepe University, Gastroenterology, Ankara, Turkey;(3)Hacettepe University, Ophtalmology, Ankara, Turkey;
1- Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis. 2007;22(9):1027-1030. doi:10.1007/s00384-007-0275-1
2- Felekis T, Katsanos K, Kitsanou M, et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis. 2009;15(1):29-34. doi:10.1002/ibd.20584
3- Nakayama LF, Bergamo VC, Conti ML, et al. The retinal foveal avascular zone as a systemic biomarker to evaluate inflammatory bowel disease control. Int J Retina Vitreous. 2019;5:16. Published 2019 Aug 6. doi:10.1186/s40942-019-0168-9
4- Debourdeau E, Charmard C, Carriere I, et al. Retinal Microcirculation Changes in Crohn's Disease Patients under Biologics, a Potential Biomarker of Severity: A Pilot Study. J Pers Med. 2022;12(2):230. Published 2022 Feb 7. doi:10.3390/jpm12020230
P0209: Unraveling the microbial dynamics in Crohn's Disease-associated Fibrosis: insights from RNA-seq and Spatial TranscriptomicsECCO'25Year: 2025
Authors: Nicolo', S.(1)*;Massimino, L.(1);Parigi, T.L.(2);Errico, C.(1);Salvatore , S.(1);Bozzetti , V.(1);Facoetti, A.(1);Cagliani, S.(1);Riva, M.(1);Danese, S.(2);Ungaro , F.(1);
(1)IRCCS San Raffaele Scientific Institute, Division of Immunology Transplantation and Infectious Diseases - Experimental Gastroenterology Unit, Milan, Italy;(2)IRCCS Hospital San Raffaele, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;
1. Massimino, L. et al. The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework. Nat. Comput. Sci. 1, 511–515 (2021).
2. Watanabe, D. & Kamada, N. Contribution of the gut microbiota to intestinal fibrosis in crohn’s disease. Front Med (Lausanne) 9, 826240 (2022).
P0210: ORMDL proteins regulate intestinal epithelial cell homeostasis by modulating ER architecture, autophagy, and DNA damage responseECCO'25Year: 2025
Authors: Raschdorf, C.(1)*;Tran, F.(1,2);Stengel, S.(1);Yang, H.(1);Pimenta Bernardes, J.(1);Lopez-Agudero, V.(1);Falk-Paulsen, M.(1);Jentzsch, M.(1);Bordoni, D.(1);Messner, B.(1);Aden, K.(1);Kaser, A.(3);Rosenstiel, P.(1);
(1)Kiel University and University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany;(2)University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(3)University of Cambridge, Department of Medicine, Cambridge, United Kingdom;
1. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 2008;40(8):955-962. doi:10.1038/ng.175
2. McGovern DPB, Gardet A, Törkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat. Genet. 2010;42(4):332-337. doi:10.1038/ng.549
3. Hjelmqvist L, Tuson M, Marfany G, Herrero E, Balcells S, Gonzàlez-Duarte R. ORMDL proteins are a conserved new family of endoplasmic reticulum membrane proteins. Genome Biol. 2002;3(6). doi:10.1186/gb-2002-3-6-research0027
4. Kiefer K, Carreras-Sureda A, García-López R, et al. Coordinated Regulation of the Orosomucoid-like Gene Family Expression Controls de Novo Ceramide Synthesis in Mammalian Cells. J. Biol. Chem. 2014;290(5):2822-2830. doi:10.1074/jbc.m114.595116
